Precision Oncology
Predicting platinum treatment survival before therapy begins
Recent Releases
-
![]()
Presenting at ELCC
CHOSA will present new research at the European Lung Cancer Conference 2026 on March 26. Abstract: mRNA profile to predict platin sensitivity in NSCLC: A translational analysis of the ETOP/EORTC SPLENDOUR Trial (459P)
-
![]()
Join us - 26th March
Join CHOSA Oncology for a webinar on Platin-DRP® and patient selection in NSCLC following the ELCC presentation. The webinar will be on the 26th of March at 17.00 CET. Register via the link below.
-
![]()
New Patent filed
CHOSA Oncology has filed a patent application covering predictive methods to support treatment decisions involving platinum-based therapies in combination with immunotherapy.
-
![]()
Platin remains key
Updated guidelines and a meta-analysis underline platinum’s key role in combination lung cancer therapy.
-
![]()
ESMO 2025 Poster
CHOSA presents 5th clinical validation of Platin-DRP® in carboplatin-treated metastatic breast cancerat ESMO 2025.
-
![]()
Økonomisk Ugebrev
Our CCO presented at Økonomisk Ugebrev’s Investor Konference giving key insights into our current milestones, and our outlook for the year ahead.
-
![]()
Significant correlation
In collaboration with ETOP and EORTC, Platin-DRP® demonstrates significant correlation with survival outcomes in NSCLC (30 Sept 2025)
-
![]()
Finalist at Jiangning 2025
CHOSA finishes as one of the 3 winners at Jiangning 2025 International Entrepreneurship Contest in Nanjing, meeting investors and partners in China’s dynamic innovation hub late this September (Photo by Ling Tang)
The Platin-DRP® is designed to bring tumor biology into platinum treatment decisions. By analyzing gene expression from a routine biopsy, the Platin-DRP® generates a score that estimates a patient’s likelihood of benefiting from cisplatin or carboplatin.
By identifying patients more likely to respond, and those less likely to benefit, Platin-DRP® enables a more precise use of standard platinum regimens. This approach has the potential to improve response rates while reducing unnecessary exposure in patients unlikely to benefit.
Biology-driven platinum selection
Different Tumors.
Same Treatment Decisions.
Platinum therapies such as cisplatin and carboplatin remain cornerstone treatments for many solid tumors, yet patient responses vary widely due to biological differences. Today, treatment decisions are often made without knowing in advance who is most likely to benefit. As a result, many patients receive treatments chosen for the population as a whole, despite significant biological differences between tumors.
Advance precision oncology through biology driven platinum treatment selection
Enabling smarter platinum use across oncology
For Patients
Personalized selection based on predicted platinum sensitivity
Reduced exposure to unnecessary toxicity
Avoiding lost time on treatments unlikely to work
Earlier access to alternative options when appropriate
More precise. Less toxicity.
For Healthcare
Improved alignment between tumor biology and therapy
Objective decision support for platinum treatment
Rapid, actionable scoring compatible with clinical workflows
More efficient use of resources within standard regimens
Biology-driven support within routine care.
Biomarker-driven enrichment of responder populations
Improved signal clarity in clinical and real-world data
More efficient development and evaluation of platinum regimens
Differentiation in competitive oncology markets
Smarter stratification. Stronger positioning.For Partners
Our support from leading oncologists
We’re honored by the strong support of seven prominent Key Opinion Leaders (KOLs) in the fields of lung, breast, bladder, and endometrial cancer. Their endorsement enhances the credibility of our Platin-DRP® and advances our mission toward precision oncology.
Dr. Fred Hirsch“We need to figure out how to select the right treatment to the right patients. So that is where the future goes. We are leaving the concept of one size fits all.”